好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Illuminating the Presentation of Hereditary Spastic Paraplegia Type 7 (HSP7)
Movement Disorders
P8 - Poster Session 8 (8:00 AM-9:00 AM)
5-023
To broaden understanding of hereditary spastic paraplegias.
Hereditary spastic paraplegias (HSPs) are inherited disorders characterized by progressive spastic paraplegia in the lower extremities. Over 80 subtypes have been described; however, clinical recognition of these diseases remains challenging. We present a series of individuals with hereditary spastic paraplegia type 7 (HSP7), highlighting one’s diagnostic odyssey.
Descriptive case series.

An 81-year-old male presented to the neurogenetics clinic for evaluation of progressive gait dysfunction that began in his 30s and progressed to full-time wheelchair dependence at age 77. He had no family members with similar symptoms. He underwent genetic testing for spinocerebellar ataxias type 1, 2, 3, 6, and 7 at age 56 that was unrevealing. Exam findings included saccadic intrusions, mild to moderate dysarthria, and moderate asymmetric lower extremity spasticity. Brain MRI showed cerebellar atrophy since at least age 65, with more recent imaging showing thinning of the corpus callosum. The patient’s wife had noticed some cognitive decline. A multi-gene panel testing for 78 known HSP-associated genes was sent, and revealed homozygosity for SPG7 (c.1529C>T, p.Ala150Val), consistent with diagnosis of autosomal recessive HSP7.

Review of seven additional patients with HSP7 reveals an average delay of 15.34 years between symptom onset and molecular diagnosis. Other common findings included ataxia, cerebellar atrophy, and later-onset of cognitive impairment. Progression to the use of assistive gait devices occurred over decades.

HSP7 can be challenging to recognize clinically, with several factors contributing to decades of diagnostic delay. It commonly presents with ataxia and a negative family history due to its recessive inheritance, which may focus the workup on sporadic cerebellar etiologies. The high incidence of cognitive impairment in this cohort suggests utility of routine neuropsychological evaluation. Increased awareness of HSP7 and other HSPs will reduce diagnostic delays and help providers serve this rare disease population effectively.
Authors/Disclosures
Emma A. Snyder, MS, CGC (Genetic Counselor)
PRESENTER
Ms. Snyder has nothing to disclose.
John Sanderson, MD (University of Washington Department of Internal Medicine) Dr. Sanderson has nothing to disclose.
Thomas D. Bird, MD, FAAN Dr. Bird has nothing to disclose.
Marie Y. Davis, MD, PhD (VA Puget Sound) Dr. Davis has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. The institution of Dr. Davis has received research support from NIH NINDS. The institution of Dr. Davis has received research support from University of Washington Institute for Stem Cell and Regenerative Medicine. The institution of Dr. Davis has received research support from VA BLRD. Dr. Davis has received personal compensation in the range of $500-$4,999 for serving as a study section grant reviewer with NIH. Dr. Davis has received personal compensation in the range of $500-$4,999 for serving as a Grant reviewer with Parkinson's Foundation.